Kalbe Farma plans IDR 500 billion buyback for Kalbe Farma stock

Published on 10/22/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 14.00 percent at Kalbe Farma on July 31, 2026. Kalbe Farma stock costs EUR 0.04 on October 22, 2026.

Corporate action and operating figures

Kalbe Farma prepared an IDR 500.0 billion buyback for September 17, 2026.
First-half 2026 net sales rose 14.00 percent to IDR 19.48 trillion.
Kalbe Farma stock trades at EUR 0.04 at 9:43 a.m. CEST at Lang & Schwarz on October 22, 2026.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ISIN ID1000125107) is preparing an IDR 500.0 billion share buyback while its stock was trading at EUR 0.04 at Lang & Schwarz on October 22, 2026 at 9:43 a.m. CEST. Fortune Indonesia reported on October 21, 2026, that the program carries a maximum allocation of IDR 500.0 billion and runs from September 17 to December 17, 2026.

Buyback meets margin pressure

The corporate action gives the stock a capital-allocation angle, but Kalbe's latest reported figures show why profitability remains central. In a September 28, 2026 report, Kontan said the buyback could lift earnings per share by 1.10 percent, while estimated lost interest income stood at IDR 8.4 billion.

Kalbe Farma reported on July 31, 2026, that first-half 2026 net sales grew 14.00 percent, driven by its prescription pharmaceutical, consumer health, nutritionals, and distribution and logistics divisions.

What does the buyback mean?

The main counterweight is the margin trend. First-half revenue reached IDR 19.48 trillion, up 14.05 percent from the comparable period, while net income fell 2.74 percent to IDR 1.97 trillion, according to TradingView. Gross margin declined to 37.56 percent from 41.14 percent as cost of sales increased 20.97 percent to IDR 12.16 trillion.

Three dated company developments

On July 31, 2026, Kalbe reported 14.00 percent first-half net sales growth. On September 17, 2026, its IDR 500.0 billion buyback period began, as reported by Kontan. On October 21, 2026, Fortune Indonesia listed the same IDR 500.0 billion allocation among active Indonesian buyback programs.

Upcoming dates for Kalbe

Investing.com lists November 3, 2026, as Kalbe Farma's next earnings date. The buyback period is scheduled to run through December 17, 2026, according to Fortune Indonesia.

Stock remains tied to execution

The combination of double-digit sales growth and lower net income leaves execution as the key issue for the stock. The buyback may support per-share earnings, but the cost base and gross margin will determine whether revenue growth converts into stronger profits.

Kalbe Farma stock was trading at EUR 0.04 at Lang & Schwarz on October 22, 2026 at 9:43 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.